Table 5.
The solicited local and systemic adverse events within seven days following a primary series of COVID-19 vaccination, stratified by the COVID-19 vaccine regimen.
| Adverse Events a | CoronaVac/ CoronaVac |
AZD1222/ AZD1222 |
CoronaVac/ AZD1222 |
AZD1222/ BNT162b2 |
BNT162b2/ BNT162b2 |
P b |
|---|---|---|---|---|---|---|
| First dose of vaccine | (n = 286) | (n = 221) | (n = 109) | (n = 100) | (n = 83) | |
| Overall adverse events | 164 (57.3) | 179 (81.0) | 62 (56.9) | 90 (90.0) | 78 (94.0) | <0.001 |
| Local adverse events | ||||||
| Pain | 116 (40.6) | 132 (59.7) | 28 (25.7) | 74 (74.0) | 77 (92.8) | <0.001 |
| Swelling | 6 (2.1) | 29 (13.1) | 3 (2.8) | 11 (11.0) | 18 (21.7) | <0.001 |
| Erythema | 4 (1.4) | 14 (6.3) | 5 (4.6) | 10 (10.0) | 4 (4.8) | 0.002 |
| Systemic adverse events | ||||||
| Fatigue | 87 (30.4) | 94 (42.5) | 41 (37.6) | 61 (61.0) | 33 (39.8) | <0.001 |
| Headache | 50 (17.5) | 72 (32.6) | 20 (18.4) | 43 (43.0) | 16 (19.3) | <0.001 |
| Fever | 11 (3.9) | 64 (29.0) | 13 (11.9) | 52 (52.0) | 14 (16.9) | <0.001 |
| Paresthesia | 10 (3.5) | 12 (5.4) | 6 (5.5) | 3 (3.0) | 2 (2.4) | 0.65 |
| Dizziness | 5 (1.8) | 7 (3.2) | 4 (3.7) | 5 (5.0) | 0 (0) | 0.16 |
| Second dose of vaccine | (n = 286) | (n = 209) | (n = 100) | (n = 120) | (n = 76) | |
| Overall adverse events | 164 (57.3) | 149 (71.3) | 76 (76.0) | 82 (68.3) | 73 (96.1) | <0.001 |
| Local adverse events | ||||||
| Pain | 139 (48.6) | 100 (47.9) | 60 (60.0) | 74 (61.7) | 71 (93.4) | <0.001 |
| Swelling | 7 (2.5) | 20 (9.6) | 14 (14.0) | 21 (17.5) | 27 (35.5) | <0.001 |
| Erythema | 4 (1.4) | 19 (9.1) | 5 (5.0) | 11 (9.2) | 11 (14.5) | <0.001 |
| Systemic adverse events | ||||||
| Fatigue | 77 (26.9) | 61 (29.2) | 45 (45.0) | 49 (40.8) | 32 (42.1) | 0.001 |
| Headache | 41 (14.3) | 53 (25.4) | 42 (42.0) | 27 (22.5) | 33 (43.4) | <0.001 |
| Fever | 11 (3.9) | 32 (15.3) | 41 (41.0) | 32 (26.7) | 24 (31.6) | <0.001 |
| Paresthesia | 12 (4.2) | 5 (2.4) | 8 (8.0) | 5 (4.2) | 2 (2.6) | 0.24 |
| Dizziness | 3 (1.1) | 6 (2.9) | 4 (4.0) | 1 (0.8) | 3 (4.0) | 0.14 |
Abbreviations: AZD1222 vaccine, the Oxford-AstraZeneca COVID-19 vaccine; BNT162b2, Pfizer-BioNTech vaccine; COVID-19, coronavirus disease 2019; a Data were presented as number (percentage); b The comparison of adverse events between groups of study participants was performed using the Chi-squared test or the Fisher’s exact test (if less than 5 observations).